Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the Phase 3 study of dupilumab in patients with uncontrolled, persistent asthma met its two primary endpoints. However, investors were disappointed after the reported reduction in severe asthma attacks was less impressive than it had been in the company's Phase 2 study.
from RTT - Before the Bell http://ift.tt/2w3VGc7
via IFTTT
No comments:
Post a Comment